vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and FS Bancorp, Inc. (FSBW). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $40.0M, roughly 1.9× FS Bancorp, Inc.). On growth, FS Bancorp, Inc. posted the faster year-over-year revenue change (12.0% vs -16.8%). Over the past eight quarters, FS Bancorp, Inc.'s revenue compounded faster (6.2% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

FS Bancorp, Inc. is a U.S.-headquartered bank holding company that serves as the parent of 1st Security Bank of Washington. It offers a full range of personal and commercial banking solutions including deposit products, mortgage loans, small business financing and construction loans, primarily catering to customers in the Pacific Northwest, with core segments covering retail banking, commercial banking and residential lending.

BIOX vs FSBW — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.9× larger
BIOX
$77.6M
$40.0M
FSBW
Growing faster (revenue YoY)
FSBW
FSBW
+28.8% gap
FSBW
12.0%
-16.8%
BIOX
Faster 2-yr revenue CAGR
FSBW
FSBW
Annualised
FSBW
6.2%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
FSBW
FSBW
Revenue
$77.6M
$40.0M
Net Profit
$-7.4M
Gross Margin
46.8%
Operating Margin
9.3%
25.8%
Net Margin
-9.6%
Revenue YoY
-16.8%
12.0%
Net Profit YoY
-20.2%
EPS (diluted)
$-0.12
$1.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
FSBW
FSBW
Q4 25
$40.0M
Q3 25
$77.6M
$39.3M
Q2 25
$37.3M
Q1 25
$60.6M
$36.1M
Q4 24
$98.8M
$35.7M
Q3 24
$93.3M
$37.2M
Q2 24
$36.3M
Q1 24
$84.0M
$35.5M
Net Profit
BIOX
BIOX
FSBW
FSBW
Q4 25
Q3 25
$-7.4M
$9.2M
Q2 25
$7.7M
Q1 25
$-1.6M
$8.0M
Q4 24
$605.2K
Q3 24
$-6.2M
$10.3M
Q2 24
$9.0M
Q1 24
$9.8M
$8.4M
Gross Margin
BIOX
BIOX
FSBW
FSBW
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
FSBW
FSBW
Q4 25
25.8%
Q3 25
9.3%
29.5%
Q2 25
26.2%
Q1 25
1.5%
26.2%
Q4 24
14.5%
27.6%
Q3 24
2.5%
26.5%
Q2 24
31.3%
Q1 24
15.7%
29.7%
Net Margin
BIOX
BIOX
FSBW
FSBW
Q4 25
Q3 25
-9.6%
23.4%
Q2 25
20.7%
Q1 25
-2.6%
22.2%
Q4 24
0.6%
Q3 24
-6.6%
27.6%
Q2 24
24.7%
Q1 24
11.6%
23.7%
EPS (diluted)
BIOX
BIOX
FSBW
FSBW
Q4 25
$1.11
Q3 25
$-0.12
$1.18
Q2 25
$0.99
Q1 25
$-0.02
$1.01
Q4 24
$0.00
$0.88
Q3 24
$-0.10
$1.29
Q2 24
$1.13
Q1 24
$0.14
$1.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
FSBW
FSBW
Cash + ST InvestmentsLiquidity on hand
$15.5M
$28.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$307.7M
Total Assets
$734.9M
$3.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
FSBW
FSBW
Q4 25
$28.2M
Q3 25
$15.5M
$61.3M
Q2 25
$33.2M
Q1 25
$38.5M
$62.7M
Q4 24
$29.2M
$31.6M
Q3 24
$32.3M
$40.3M
Q2 24
$33.0M
Q1 24
$16.4M
$45.4M
Stockholders' Equity
BIOX
BIOX
FSBW
FSBW
Q4 25
$307.7M
Q3 25
$288.3M
$300.5M
Q2 25
$297.2M
Q1 25
$345.0M
$298.8M
Q4 24
$346.3M
$295.8M
Q3 24
$346.0M
$288.9M
Q2 24
$284.0M
Q1 24
$348.5M
$277.9M
Total Assets
BIOX
BIOX
FSBW
FSBW
Q4 25
$3.2B
Q3 25
$734.9M
$3.2B
Q2 25
$3.2B
Q1 25
$798.2M
$3.1B
Q4 24
$835.2M
$3.0B
Q3 24
$827.3M
$3.0B
Q2 24
$2.9B
Q1 24
$836.1M
$3.0B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
FSBW
FSBW
Operating Cash FlowLast quarter
$14.4M
$72.3M
Free Cash FlowOCF − Capex
$51.9M
FCF MarginFCF / Revenue
129.8%
Capex IntensityCapex / Revenue
50.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$107.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
FSBW
FSBW
Q4 25
$72.3M
Q3 25
$14.4M
$44.6M
Q2 25
$7.1M
Q1 25
$23.3M
$8.2M
Q4 24
$-5.4M
$50.8M
Q3 24
$5.2M
$-891.0K
Q2 24
$9.9M
Q1 24
$-17.4M
$275.0K
Free Cash Flow
BIOX
BIOX
FSBW
FSBW
Q4 25
$51.9M
Q3 25
$41.6M
Q2 25
$5.9M
Q1 25
$7.8M
Q4 24
$49.2M
Q3 24
$-1.5M
Q2 24
$9.6M
Q1 24
$-82.0K
FCF Margin
BIOX
BIOX
FSBW
FSBW
Q4 25
129.8%
Q3 25
105.9%
Q2 25
15.7%
Q1 25
21.7%
Q4 24
137.7%
Q3 24
-4.1%
Q2 24
26.6%
Q1 24
-0.2%
Capex Intensity
BIOX
BIOX
FSBW
FSBW
Q4 25
50.9%
Q3 25
7.7%
Q2 25
3.5%
Q1 25
1.0%
Q4 24
4.6%
Q3 24
1.7%
Q2 24
0.8%
Q1 24
1.0%
Cash Conversion
BIOX
BIOX
FSBW
FSBW
Q4 25
Q3 25
4.86×
Q2 25
0.92×
Q1 25
1.02×
Q4 24
-8.85×
Q3 24
-0.09×
Q2 24
1.11×
Q1 24
-1.78×
0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons